PubMed Health⌕ Search

Biomedical subjects

C Hernández-Guío

Publications and source records attributed to C Hernández-Guío.

6 recordsLinked to original sources
PubMed1993

[Changes in serum levels of beta 2-microglobulin, neopterin and 2',5'-oligoadenylate synthase activity during clearance of hepatitis B virus with or without acute phase in transaminases].

We have investigated the relation between acute-like transaminase exacerbations and the induction of 2',5'-oligoadenylate (2-5A) synthetase activity, HLA-I associated beta 2-microglobulin and macrophage activated release of neopterin during hepatitis B virus clearance in 70 patients treated or not with interferon. In treated patients who had an exacerbation in ALT during HBV clearance (loss of HBeAg and HBV-DNA from serum), the activity of the enzyme 2-5A synthetase and the level of beta 2 microglobulin increased markedly (p < 0.05). In contrast, in the absence of a peak in ALT during HBV clearance following interferon administration, the levels of 2-5A synthetase activity and neopterin, but not of beta 2-microglobulin, rose significantly (p < 0.05). Neither the non-responder treated patients nor the untreated controls had significant changes in these parameters, irrespective of the transaminase levels. Thus, elimination of viremia after interferon treatment may occur by different pathways as reflected by the presence or absence of acute-like biochemical exacerbations.

2',5'-Oligoadenylate Synthetase↗
PubMed1985

Radioimmunoassay for detecting hepatitis B core antigen in serum from patients with chronic hepatitis B infection.

The core antigen component of hepatitis B virus (HBV), HBcAg, may be used as a marker of viral replication. We describe a radioimmunoassay for HBcAg in serum, and compare results with those by other similar methods. Samples are centrifuged over a sucrose gradient containing 2-mercaptoethanol, and the resulting pellets are resuspended in a nonionic detergent solution. After a bead coated with anti-HBcAg is incubated with this suspension, 125I-labeled anti-HBcAg is added, and is also bound by the antigen. The specificity of the method was verified by blocking with purified IgG antibodies to HBcAg. When we tested by this method for HBcAg in sera from 60 patients with chronic HBV infection, all those with circulating HBV-DNA polymerase tested positive for HBcAg. All sera from HBV-negative controls showed no detectable HBcAg. The correlation between the presence of HBcAg and HBV-DNA polymerase was significant (r = 0.715, p less than 0.001). Samples can be tested more quickly and easily with this method, and its sensitivity compares well with that of other similar methods.

Chronic Disease↗
PubMed1975

Role of HBs Ab in development of hepatitis.

24% of a healthy control population had antibody to hepatitis-B surface antigen (HBsAb) detectable by passive haemagglutination. The frequency was higher in other population groups in proportion to the intensity of contract with individuals or material positive for HBsAg. Data obtained during an outbreak of type-B hepatitis indicate that immunity to the disease is directly dependent on the titre of circulating HBsAb. A close relationship was found between the presence of HBsAb and liver dysfunction in carriers of HBsAg. This supports the hypothesis that immune response to the antigen may be necessary for the development of liver damage in type-B hepatitis. Nevertheless, since a good antibody response to HBsAg was found in uraemic patients, in whom hepatitis had a clinical course quite different from the population at large, it is thought that immune mechanisms other than the humoral response may account for the pathogenesis of the disease.

Adolescent↗